Study genes in neuroblastic tumors and compare with outcomes
Part of Cancer clinical trials.
This study looks at the tumor’s molecular (genetic) features in people with neuroblastic tumors to see how those features relate to clinical outcomes. If you are treated with naxitamab as part of standard care, you may be eligible for the tumor/biomarker (test results) portion of the research.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a neuroblastic tumor using the standard staging system OR your doctors strongly suspect one
- For the blood-timing portion, you receive naxitamab as part of your usual care
- There are no listed exclusion criteria in the provided eligibility information
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects blood samples from neuroblastoma patients to test for tiny pieces of tumor DNA that can show how well treatment is working. By tracking these markers over time, doctors hope to better predict how patients will respond and improve care.
This Phase 2 trial tests whether adding a drug called naxitamab to standard early (frontline) treatment improves outcomes for children with high-risk neuroblastoma. It may help by helping the immune system better target the cancer during initial induction therapy.
This study looks at how high-risk neuroblastoma grows and behaves by collecting samples from your child and checking disease markers. It may help researchers understand what biology is driving the cancer and guide future treatments.
This trial tests giving a combination of naxitamab, irinotecan, and temozolomide for a longer period to people whose neuroblastoma has come back or hasn't responded to standard treatments. The goal is to see if this approach is safe and effective.
This study creates an international registry linked to a virtual biobank, so researchers can collect and share information and biological samples for patients with specific peripheral neuroblastic tumors. It may help future research and care planning by improving what scientists know about these conditions.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.